FDA raises manufacturing concerns at CryoLife
by The Atlanta Business Chronicle
Feb 18, 2013 | 692 views | 0 0 comments | 2 2 recommendations | email to a friend | print
The Food and Drug Administration has raised concerns about manufacturing and management processes at CryoLife Inc.

The Kennesaw, Ga.-based company (NYSE: CRY) is an implantable biological medical device and cardiovascular tissue processing company.

In the early aughts, CryoLife paid millions of dollars to settle suits involving allegedly contaminated tissue products. In July 2005, CryoLife reached a $23.3 million settlement for a class-action lawsuit that alleged it had inadequate disclosures prior to the FDA's August 2002 tissue recall.

Click here to continue reading.
Comments
(0)
Comments-icon Post a Comment
No Comments Yet
Postings are not edited and are the responsibility of the author. You agree not to post comments that are abusive, threatening or obscene. Postings may be removed at our discretion.